<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eli Lilly And Company — News on 6ix</title>
<link>https://6ix.com/company/eli-lilly-and-company</link>
<description>Latest news and press releases for Eli Lilly And Company on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 15:11:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eli-lilly-and-company" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835924878dffbe2df102cef.webp</url>
<title>Eli Lilly And Company</title>
<link>https://6ix.com/company/eli-lilly-and-company</link>
</image>
<item>
<title>Lilly declares second-quarter 2026 dividend</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-declares-second-quarter-2026-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-declares-second-quarter-2026-dividend</guid>
<pubDate>Mon, 04 May 2026 15:11:00 GMT</pubDate>
<description>The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock.</description>
</item>
<item>
<title>Trulicity Market Size to Reach USD 15.30 Billion by 2035 with Strong Demand for Metabolic Treatments | SNS Insider</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/trulicity-market-size-to-reach-usd-1530-billion-by-2035-with-strong-demand-for-metabolic-treatments-or-sns-insider</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/trulicity-market-size-to-reach-usd-1530-billion-by-2035-with-strong-demand-for-metabolic-treatments-or-sns-insider</guid>
<pubDate>Mon, 04 May 2026 11:18:00 GMT</pubDate>
<description>U.S. Trulicity Market to Reach USD 4.87 Billion by 2035 Driven by Rising Diabetes PrevalenceAustin, May 04, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Trulicity Market size was valued at USD 7.03 Billion in 2025 and is expected to reach USD 15.30 Billion by 2035, growing at a CAGR of 8.16% during the forecast period 2026–2035. The global Trulicity market is experiencing exponential growth due to the rise in cases of type 2 diabetes and obesity in different parts of the globe. The ris</description>
</item>
<item>
<title>Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-reports-first-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-momentum-of-new-medicines</guid>
<pubDate>Thu, 30 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2026 and provided updated 2026 financial guidance.</description>
</item>
<item>
<title>Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/retatrutide-crosses-the-surgical-threshold-but-the-real-race-has-just-started</guid>
<pubDate>Wed, 29 Apr 2026 15:00:00 GMT</pubDate>
<description>Dallas, TX, April 29, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse: “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.” In April 2026, Eli Lilly’s retatrutide delivered 28.7% mean weight loss, the first non-surgical therapy to match bariatric outcomes. But the milestone didn’t end the race. It changes it. Everyone is focused on the 28.7%,” said Will Rosellini - Chief IP Officer at PatentVest.“But that</description>
</item>
<item>
<title>Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicine</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/profluent-announces-strategic-partnership-with-lilly-to-develop-ai-designed-recombinases-for-genetic-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/profluent-announces-strategic-partnership-with-lilly-to-develop-ai-designed-recombinases-for-genetic-medicine</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., April 28, 2026--Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly and Company ("Lilly") to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs.</description>
</item>
<item>
<title>Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-ajax-therapeutics-to-advance-outcomes-for-patients-with-myelofibrosis-and-polycythemia-vera</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-ajax-therapeutics-to-advance-outcomes-for-patients-with-myelofibrosis-and-polycythemia-vera</guid>
<pubDate>Mon, 27 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Lilly to acquire Ajax. Ajax's lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a Phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously been treated w</description>
</item>
<item>
<title>Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/spherix-global-insights-finds-specialty-split-in-perceptions-of-direct-to-patient-platforms-for-obesity-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/spherix-global-insights-finds-specialty-split-in-perceptions-of-direct-to-patient-platforms-for-obesity-treatment</guid>
<pubDate>Fri, 24 Apr 2026 14:18:00 GMT</pubDate>
<description>High adoption rates for obesity treatment are noted across both LillyDirect and NovoCare platforms, but key workflow differences drive a split in preferencesExton, PA, April 24, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape evolves, new access channels are reshaping how patients receive care. Since the launch of Eli Lilly’s LillyDirect in January 2024 and Novo Nordisk’s NovoCare pharmacy in March 2025, physicians are increasingly incorporating manufacturer direct-to-patient platfor</description>
</item>
<item>
<title>Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies</guid>
<pubDate>Mon, 20 Apr 2026 13:00:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.</description>
</item>
<item>
<title>Lilly confirms date and conference call for first-quarter 2026 financial results announcement</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lilly-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lilly-confirms-date-and-conference-call-for-first-quarter-2026-financial-results-announcement</guid>
<pubDate>Thu, 16 Apr 2026 14:00:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.</description>
</item>
<item>
<title>ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/achieve-4-the-longest-phase-3-study-of-lillys-foundayo-orforglipron-to-date-reaffirmed-its-cardiovascular-and-overall-safety-profile-as-well-as-consistent-improvements-across-key-measures-of-cardiometabolic-health</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/achieve-4-the-longest-phase-3-study-of-lillys-foundayo-orforglipron-to-date-reaffirmed-its-cardiovascular-and-overall-safety-profile-as-well-as-consistent-improvements-across-key-measures-of-cardiometabolic-health</guid>
<pubDate>Thu, 16 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes to date, enrolled more than 2,700 participants across 15 countries. In the trial, Foundayo met the primary endpoint by demonstrating a no</description>
</item>
<item>
<title>Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/shed-adds-foundayotm-to-its-platform-expanding-oral-glp-1-access-for-patients-nationwide</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/shed-adds-foundayotm-to-its-platform-expanding-oral-glp-1-access-for-patients-nationwide</guid>
<pubDate>Wed, 15 Apr 2026 12:21:00 GMT</pubDate>
<description>Shed, a leading online health and wellness platform, today announced it is now offering Foundayo™ (orforglipron), Eli Lilly and Company's FDA-approved once-daily oral GLP-1 therapy for weight management. The addition gives Shed members a clinically proven, needle-free alternative to injectable GLP-1 treatments — one that requires no special meal timing and fits naturally into everyday life.</description>
</item>
<item>
<title>Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/vasa-therapeutics-partners-with-lilly-tunelab-to-power-aiml-driven-camkii-inhibitor-platform</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/vasa-therapeutics-partners-with-lilly-tunelab-to-power-aiml-driven-camkii-inhibitor-platform</guid>
<pubDate>Tue, 14 Apr 2026 12:00:00 GMT</pubDate>
<description>Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("Lilly") that enables the company to utilize Lilly TuneLab, an AI-enabled drug discovery platform that provides biotech companies access to drug discovery models trained on Lilly's proprietary data.</description>
</item>
<item>
<title>Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cllsll</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lillys-jaypirca-pirtobrutinib-significantly-extended-progression-free-survival-when-added-to-a-venetoclax-time-limited-regimen-in-patients-with-previously-treated-cllsll</guid>
<pubDate>Mon, 13 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). Treatment in both study arms was administered for up to two years, after which patients do not take any CLL therapy unt</description>
</item>
<item>
<title>LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/lifemdr-now-offering-eli-lilly-and-companys-foundayotm-orforglipron-a-new-glp-1-pill-for-weight-management-1</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/lifemdr-now-offering-eli-lilly-and-companys-foundayotm-orforglipron-a-new-glp-1-pill-for-weight-management-1</guid>
<pubDate>Fri, 10 Apr 2026 12:15:00 GMT</pubDate>
<description>LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatmen</description>
</item>
<item>
<title>Weight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/weight-watchers-launches-eli-lilly-and-companys-new-oral-glp-1-foundayor-available-through-lillydirect</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/weight-watchers-launches-eli-lilly-and-companys-new-oral-glp-1-foundayor-available-through-lillydirect</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>The addition of Foundayo® (orforglipron) gives Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for weight lossNEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company’s newly FDA-approved oral GLP-1, Foundayo® (orforglipron) through its Med+ offering and affiliated medical groups. The addition gives members a new o</description>
</item>
<item>
<title>RO OFFERS ELI LILLY'S FOUNDAYO™, THE NEWEST GLP-1 INNOVATION</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/ro-offers-eli-lillys-foundayotm-the-newest-glp-1-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/ro-offers-eli-lillys-foundayotm-the-newest-glp-1-innovation</guid>
<pubDate>Thu, 09 Apr 2026 11:15:00 GMT</pubDate>
<description>Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo™ (orforglipron) – Eli Lilly Company's newest oral GLP-1 innovation – on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s. Foundayo™ is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems.</description>
</item>
<item>
<title>Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-us</guid>
<pubDate>Thu, 09 Apr 2026 10:45:00 GMT</pubDate>
<description>Eli Lilly and Company (NYSE: LLY) today announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo is a once-daily pill for weight loss that can be taken without food or water restrictio</description>
</item>
<item>
<title>Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/nxera-pharma-achieves-second-development-milestone-in-collaboration-with-eli-lilly-targeting-metabolic-diseases-1</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/nxera-pharma-achieves-second-development-milestone-in-collaboration-with-eli-lilly-targeting-metabolic-diseases-1</guid>
<pubDate>Wed, 08 Apr 2026 23:34:00 GMT</pubDate>
<description>Tokyo, Japan and Cambridge, UK, 09 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requir</description>
</item>
<item>
<title>AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/ac-immune-announces-amendment-to-morphomer-r-tau-license-and-collaboration-agreement-with-lilly-1</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/ac-immune-announces-amendment-to-morphomer-r-tau-license-and-collaboration-agreement-with-lilly-1</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small moleculesInvestigational New Drug (IND)-enabling studies to commence in H1 2026 Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases,</description>
</item>
<item>
<title>RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®</title>
<link>https://6ix.com/company/eli-lilly-and-company/news/ro-launches-eli-lillys-kwikpenr-offering-patients-a-more-convenient-way-to-take-zepboundr</link>
<guid isPermaLink="true">https://6ix.com/company/eli-lilly-and-company/news/ro-launches-eli-lillys-kwikpenr-offering-patients-a-more-convenient-way-to-take-zepboundr</guid>
<pubDate>Thu, 02 Apr 2026 17:01:00 GMT</pubDate>
<description>Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available. Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and do</description>
</item>
</channel>
</rss>